Geode Capital Management’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Geode Capital Management’s Portfolio SGTX Stock Details SGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,423	Closed	-$89.8K	–	4837
2023 Q1	$89.8K	Sell	7,423 -2,023	-21%	-$21K	﹤0.01%	4382
2022 Q4	$42K	Buy	9,446 +32	+0.3%	+$183	﹤0.01%	4640
2022 Q3	$61K	Buy	9,414 +87	+0.9%	+$794	﹤0.01%	4721
2022 Q2	$100K	Sell	9,327 -9,687	-51%	-$130K	﹤0.01%	4595
2022 Q1	$363K	Buy	19,014 +1,002	+6%	+$22.3K	﹤0.01%	4107
2021 Q4	$646K	Buy	18,012 +192	+1%	+$10.9K	﹤0.01%	3919
2021 Q3	$1.31M	Buy	17,820 +7,530	+73%	+$579K	﹤0.01%	3546
2021 Q2	$1.44M	Buy	10,290 +910	+10%	+$160K	﹤0.01%	3425
2021 Q1	$2.73M	Buy	9,380 +8,078	+620%	+$3.21M	﹤0.01%	3109
2020 Q4	$813K	Buy	+1,302	New	+$591K	﹤0.01%	3425

Other funds holding SGTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management's SGTX Position: Q2 2023 in Review

Geode Capital Management sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2023, closing a stake of 7,423 shares — an estimated $89.8K sold.

Geode Capital Management first reported a position in SGTX in Q4 2020 and held it in 10 quarters. The position peaked at $2.73M in Q1 2021. 16 funds tracked by Wall St. Rank hold SGTX as of Q2 2023.

Geode Capital Management reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Geode Capital Management sold 7,423 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $89.8K.
Geode Capital Management first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q4 2020 and held it in 10 quarters.
Geode Capital Management's Sigilon Therapeutics, Inc. Common Stock position peaked at $2.73M in Q1 2021.
16 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Geode Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.